U.S. PHARMACOPEIA

Search USP29  
Ceftriaxone for Injection
» Ceftriaxone for Injection contains an amount of Ceftriaxone Sodium equivalent to not less than 776 µg of ceftriaxone (C18H18N8O7S3) per mg, calculated on the anhydrous basis, and the equivalent of not less than 90.0 percent and not more than 115.0 percent of the labeled amount of ceftriaxone (C18H18N8O7S3).
Packaging and storage— Preserve in Containers for Sterile Solids as described under Injections 1.
Constituted solution— At the time of use, it meets the requirements for Constituted Solutions under Injections 1.
Bacterial endotoxins 85 It contains not more than 0.20 USP Endotoxin Unit per mg of ceftriaxone.
Sterility 71 It meets the requirements when tested as directed for Membrane Filtration under Test for Sterility of the Product to be Examined.
Particulate matter 788: meets the requirements for small-volume injections.
Residual solvents 467: meets the requirements.
(Official January 1, 2007)
Other requirements— It responds to the Identification tests and meets the requirements for Crystallinity, pH, and Water under Ceftriaxone Sodium It meets also the requirements for Uniformity of Dosage Units 905 and for Labeling under Injections 1.
Assay—
pH 7.0 Buffer, pH 5.0 Buffer, Mobile phase, Standard preparation, Resolution solution, and Chromatographic system— Prepare as directed in the Assay under Ceftriaxone Sodium.
Assay preparation 1— Transfer about 40 mg of Ceftriaxone for Injection, accurately weighed, to a 200-mL volumetric flask, dissolve in and dilute with Mobile phase to volume, and mix. Use this solution promptly after preparation.
Assay preparation 2 (where it is represented as being in a single-dose container)—Constitute Ceftriaxone for Injection in a volume of water, accurately measured, corresponding to the volume of solvent specified in the labeling. Withdraw all of the withdrawable contents, using a suitable hypodermic needle and syringe, and dilute quantitatively with Mobile phase to obtain a solution containing about 180 µg of ceftriaxone per mL. Use this solution promptly after preparation.
Assay preparation 3 (where the label states the quantity of ceftriaxone in a given volume of constituted solution)—Constitute Ceftriaxone for Injection in a volume of water, accurately measured, corresponding to the volume of solvent specified in the labeling. Dilute an accurately measured volume of the constituted solution quantitatively with Mobile phase to obtain a solution containing about 180 µg of ceftriaxone per mL. Use this solution promptly after preparation.
Procedure— Proceed as directed in the Assay under Ceftriaxone Sodium. Calculate the quantity, in µg, of ceftriaxone (C18H18N8O7S3) per mg of the Ceftriaxone for Injection taken by the formula:
200(CP / W)(rU / rS),
in which C is the concentration, in mg per mL, of USP Ceftriaxone Sodium RS in the Standard preparation; P is the designated potency, in µg, of ceftriaxone per mg of USP Ceftriaxone Sodium RS; W is the quantity, in mg, of Ceftriaxone for Injection taken to prepare Assay preparation 1; and rU and rS are the ceftriaxone peak responses obtained from Assay preparation 1 and the Standard preparation, respectively. Calculate the quantity, in mg, of ceftriaxone (C18H18N8O7S3) withdrawn from the container, or in the portion of constituted solution taken by the formula:
(L / D)(CP)(rU / rS),
in which L is the labeled quantity, in mg, of ceftriaxone (C18H18 N8O7S3) in the container, or in the volume of constituted solution taken; D is the concentration, in µg per mL, of ceftriaxone in Assay preparation 2 or Assay preparation 3, based on the labeled quantity in the container or in the portion of constituted solution taken, respectively, and the extent of dilution; C is the concentration, in mg per mL, of USP Ceftriaxone Sodium RS in the Standard preparation; P is the designated potency, in µg, of ceftriaxone per mg of USP Ceftriaxone Sodium RS; and rU and rS are the ceftriaxone peak responses obtained from the Assay preparation and the Standard preparation, respectively.
Auxiliary Information— Staff Liaison : Brian D. Gilbert, Ph.D., Scientist
Expert Committee : (MDANT05) Monograph Development-Antibiotics
USP29–NF24 Page 440
Phone Number : 1-301-816-8223